首页> 外文期刊>Pediatric blood & cancer >Allogeneic hematopoietic cell transplantation in chemotherapy‐induced aplasia in children with high‐risk acute myeloid leukemia or myelodysplasia
【24h】

Allogeneic hematopoietic cell transplantation in chemotherapy‐induced aplasia in children with high‐risk acute myeloid leukemia or myelodysplasia

机译:化疗造血细胞移植在高危急性髓性白血病或髓细胞胰腺癌中的化疗诱导的血液诱导

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Relapse remains the most common cause of treatment failure after hematopoietic cell transplantation for acute myeloid leukemia. Inability to achieve hematologic complete remission has been a barrier to transplant for patients with refractory disease. We describe six children with refractory myeloid disease undergoing transplant in chemotherapy‐induced aplasia, as a strategy to facilitate curative therapy in refractory patients. Clofarabine‐ or high‐dose cytarabine‐based chemotherapy regimens were used to achieve marrow aplasia, followed by reduced‐intensity conditioning and allogeneic transplant before hematologic recovery. Long‐term disease control was achieved in five, with one transplant‐related mortality, suggesting the feasibility of this approach.
机译:摘要复发仍然是急性髓性白血病造血细胞移植后治疗失败的最常见原因。 无法实现血液学完全缓解是对难治性疾病患者移植的障碍。 我们描述了六个患有在化疗诱导的Aplasia移植的难治性骨髓疾病的患儿,作为促进难治性患者治疗治疗的策略。 基于氯苯胺或高剂量的糖氨基胺化疗方案用于实现骨髓APLASIA,然后在血液学回收前进行减少强度调节和同种异体移植。 长期疾病控制在五中实现,具有一种与移植相关的死亡率,表明这种方法的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号